phospholipase D family member 4Genealiases: C14orf175 · SLEB18
Q-omics provides the consensus-scored PLD4 profile across patient tissues and cancer cell-line models. PLD4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PLD4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLD4 RNA expression shows 20,186 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where PLD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLD4 survival associations across molecular data types. PLD4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLD4 RNA expression–survival associations across cancer types. High PLD4 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, ACC, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PLD4 RNA expression.
This table summarizes PLD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLD4 shows lower tumor expression in COAD, LUSC and UCEC and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher PLD4 RNA expression in tumor versus normal tissue (log2 FC = +1.973, t-test p < 0.001).
This table shows molecular features associated with PLD4 in patient tissues and cancer cell lines. In patient samples, PLD4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
